Medmira Inc (MMIRF) 0.0812 $MMIRF
MedMira's New Miriad™ RVF Toolkit Offers Researchers Speedier Test Results
PR Newswire - Mon Mar 10, 7:00AM CDT
Solution Brings Real-time Results and Point-of-Sampling Mobility to Research, Academic Markets
MedMira Embarks on Major U.S. Expansion with VWR International, LLC Agreement
PR Newswire - Mon Jan 13, 7:15AM CST
Deal Dramatically Increases U.S. Access to Patented Rapid Testing Technology
MedMira CEO Awarded Honorary Doctor of Science by Acadia University
CNW Group - Wed Aug 21, 7:52AM CDT
Acadia University, in Wolfville, Nova Scotia has awarded an Honorary Doctor of Science to Hermes Chan, CEO and Co-Founder of MedMira Inc. Mr. Chan took part in the celebrations for the 100(th) Anniversary of the Chemistry Department at Acadia University last week.
MedMira Reports Third Quarter Results
CNW Group - Fri Jun 28, 5:07PM CDT
MedMira Inc., (MedMira) (TSXV: MIR), a developer of rapid diagnostic technology and solutions, reported today on its financial results for the three and nine month periods ending April 30, 2013.
MedMira Fueled with Capital Injection to Advance US Market Opportunities
CNW Group - Wed Jun 05, 4:30PM CDT
MedMira Inc., (MedMira) (TSXV: MIR), a developer of rapid diagnostic technology and solutions, today announced a loan of CHF $500,000 or CAD $531,464 from OnSite Lab Holding AG (OnSite Lab).OnSite Lab is the Company's largest and controlling shareholder.
MedMira Strengthens Sales Distribution Channel in the US
CNW Group - Tue Apr 16, 8:11AM CDT
MedMira Inc., (MedMira) (TSXV: MIR), a developer of rapid diagnostic technology and solutions, announced today that it is strengthening the Company's sales and distribution channel in the United States by working directly with Cardinal Health and VWR International to sell and distribute the Reveal G3 Rapid HIV-1 Antibody Test. Previously, MedMira's agent American Health Partners maintained these relationships on behalf of the Company and effective today this contract has been concluded.
MedMira Attends FDA Public Workshop as Interest in its Multiplex Rapid Tests Continues to Increase
CNW Group - Thu Apr 11, 6:15AM CDT
MedMira Inc., (MedMira) (TSXV: MIR), a developer of rapid diagnostic technology and solutions, is attending the US Food and Drug Administration Public Workshop on advances in multiplex testing taking place this week in Bethesda, MD. Participation in this workshop is particularly timely, as MedMira advances a new multiplex rapid test for the simultaneous detection of HIV and Hepatitis B and C towards clinical trials and the FDA approval process under a United States Army Medical Research Acquisition Activity (USAMRAA) contract. It is anticipated that various branches of the US military would use the test in emergency medical situations and for screening transfusion transmitted diseases.
MedMira Reports Second Quarter Results
CNW Group - Mon Apr 01, 5:37PM CDT
MedMira Inc., (MedMira) (TSXV: MIR), a developer of rapid diagnostic technology and solutions, reported today on its financial results for the three and six month periods ending January 31, 2013.
MedMira Submits Syphilis/HIV Combination Test for WHO Approval Upon Invitation to Prequalification Program
CNW Group - Mon Mar 11, 8:09AM CDT
MedMira Inc., (MedMira) (TSXV: MIR), a developer of rapid diagnostic technology and solutions, announced today that it has submitted an application for its Multiplo Syphilis/HIV rapid test (also known as Multiplo TP/HIV) to the World Health Organization (WHO) Prequalification of Diagnostics program. The Company received a letter of invitation from the WHO to submit Multiplo Syphilis/HIV for prequalification. This invitation comes as MedMira's Reveal HIV rapid test is in the final stages of the WHO prequalification program.
MedMira Board of Directors Elected at Annual Shareholders Meeting
CNW Group - Tue Jan 29, 10:48AM CST
MedMira Inc., (MedMira) (TSXV: MIR), a developer of rapid diagnostic technology and solutions, today announced that the Company's Board of Directors was elected at MedMira's 2013 Annual General and Special Meeting of Shareholders, which was held on January 25(th), 2013. Mr. Hermes Chan, Dr. Shou-Ching Tang, Mr. Romano Robusto and Mr. Markus Meile were re-elected as Directors of the Company. Dr. Michael Sidler, a representative of the Company's majority shareholder, OnSite Lab Holding AG, was also elected.
MedMira Reports First Quarter Results with an Increase in Revenues Over Last Year
CNW Group - Fri Dec 28, 8:33PM CST
MedMira Inc., (MedMira) (TSXV: MIR), a developer of rapid diagnostic technology and solutions, reported today on its financial results for the three month period ending October 31, 2012. The Company's revenues were up by $309,728 over the same quarter last year.
MedMira's New Miriad™ RVF Toolkit Offers Researchers Speedier Test Results
PR Newswire - Mon Mar 10, 7:00AM CDT
Solution Brings Real-time Results and Point-of-Sampling Mobility to Research, Academic Markets
MedMira Embarks on Major U.S. Expansion with VWR International, LLC Agreement
PR Newswire - Mon Jan 13, 7:15AM CST
Deal Dramatically Increases U.S. Access to Patented Rapid Testing Technology
MedMira CEO Awarded Honorary Doctor of Science by Acadia University
CNW Group - Wed Aug 21, 7:52AM CDT
Acadia University, in Wolfville, Nova Scotia has awarded an Honorary Doctor of Science to Hermes Chan, CEO and Co-Founder of MedMira Inc. Mr. Chan took part in the celebrations for the 100(th) Anniversary of the Chemistry Department at Acadia University last week.
MedMira Reports Third Quarter Results
CNW Group - Fri Jun 28, 5:07PM CDT
MedMira Inc., (MedMira) (TSXV: MIR), a developer of rapid diagnostic technology and solutions, reported today on its financial results for the three and nine month periods ending April 30, 2013.
MedMira Fueled with Capital Injection to Advance US Market Opportunities
CNW Group - Wed Jun 05, 4:30PM CDT
MedMira Inc., (MedMira) (TSXV: MIR), a developer of rapid diagnostic technology and solutions, today announced a loan of CHF $500,000 or CAD $531,464 from OnSite Lab Holding AG (OnSite Lab).OnSite Lab is the Company's largest and controlling shareholder.
MedMira Strengthens Sales Distribution Channel in the US
CNW Group - Tue Apr 16, 8:11AM CDT
MedMira Inc., (MedMira) (TSXV: MIR), a developer of rapid diagnostic technology and solutions, announced today that it is strengthening the Company's sales and distribution channel in the United States by working directly with Cardinal Health and VWR International to sell and distribute the Reveal G3 Rapid HIV-1 Antibody Test. Previously, MedMira's agent American Health Partners maintained these relationships on behalf of the Company and effective today this contract has been concluded.
MedMira Attends FDA Public Workshop as Interest in its Multiplex Rapid Tests Continues to Increase
CNW Group - Thu Apr 11, 6:15AM CDT
MedMira Inc., (MedMira) (TSXV: MIR), a developer of rapid diagnostic technology and solutions, is attending the US Food and Drug Administration Public Workshop on advances in multiplex testing taking place this week in Bethesda, MD. Participation in this workshop is particularly timely, as MedMira advances a new multiplex rapid test for the simultaneous detection of HIV and Hepatitis B and C towards clinical trials and the FDA approval process under a United States Army Medical Research Acquisition Activity (USAMRAA) contract. It is anticipated that various branches of the US military would use the test in emergency medical situations and for screening transfusion transmitted diseases.
MedMira Reports Second Quarter Results
CNW Group - Mon Apr 01, 5:37PM CDT
MedMira Inc., (MedMira) (TSXV: MIR), a developer of rapid diagnostic technology and solutions, reported today on its financial results for the three and six month periods ending January 31, 2013.
MedMira Submits Syphilis/HIV Combination Test for WHO Approval Upon Invitation to Prequalification Program
CNW Group - Mon Mar 11, 8:09AM CDT
MedMira Inc., (MedMira) (TSXV: MIR), a developer of rapid diagnostic technology and solutions, announced today that it has submitted an application for its Multiplo Syphilis/HIV rapid test (also known as Multiplo TP/HIV) to the World Health Organization (WHO) Prequalification of Diagnostics program. The Company received a letter of invitation from the WHO to submit Multiplo Syphilis/HIV for prequalification. This invitation comes as MedMira's Reveal HIV rapid test is in the final stages of the WHO prequalification program.
MedMira Board of Directors Elected at Annual Shareholders Meeting
CNW Group - Tue Jan 29, 10:48AM CST
MedMira Inc., (MedMira) (TSXV: MIR), a developer of rapid diagnostic technology and solutions, today announced that the Company's Board of Directors was elected at MedMira's 2013 Annual General and Special Meeting of Shareholders, which was held on January 25(th), 2013. Mr. Hermes Chan, Dr. Shou-Ching Tang, Mr. Romano Robusto and Mr. Markus Meile were re-elected as Directors of the Company. Dr. Michael Sidler, a representative of the Company's majority shareholder, OnSite Lab Holding AG, was also elected.
MedMira Reports First Quarter Results with an Increase in Revenues Over Last Year
CNW Group - Fri Dec 28, 8:33PM CST
MedMira Inc., (MedMira) (TSXV: MIR), a developer of rapid diagnostic technology and solutions, reported today on its financial results for the three month period ending October 31, 2012. The Company's revenues were up by $309,728 over the same quarter last year.
